Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
AstraZeneca
Merck Sharp & Dohme LLC
Genmab
Mayo Clinic
BioNTech SE
Aminex Therapeutics, Inc.
Toray Industries, Inc
STORM Therapeutics LTD
Neonc Technologies, Inc.
Hummingbird Bioscience
University of Wisconsin, Madison
Ipsen
Bristol-Myers Squibb
Bristol-Myers Squibb
Children's Oncology Group
Diakonos Oncology Corporation
Duke University
Arvinas Inc.
Immatics US, Inc.
BioInvent International AB
Aulos Bioscience, Inc.
M.D. Anderson Cancer Center
Essen Biotech
Essen Biotech